Harvard Bioscience Analyst Price Targets

Wall Street analyst price targets and consensus rating for Harvard Bioscience (HBIO).

Price Target Range — 5 Quarters

Analyst Consensus

Consensus RatingSpeculative BuyAvg. Consensus PT$19Upside to Avg. PT+114.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 12, 2026	Benchmark	Bruce D. Jackson	PT Raise	Speculative Buy	$6→$8
Mar 16, 2026	Benchmark	Bruce D. Jackson	PT Raise	Speculative Buy	$1→$6
Mar 13, 2026	Benchmark	Bruce D. Jackson	PT Cut	Speculative Buy	$2→$1
Sep 10, 2025	Benchmark	Bruce D. Jackson	PT Cut	Speculative Buy	$3→$2
May 13, 2025	Benchmark	Bruce Jackson	PT Cut	Speculative Buy	$5→$3
Apr 9, 2025	Keybanc	Paul Knight	Downgrade	Overweight→Sector Weight	—
Mar 24, 2025	Benchmark	Bruce Jackson	PT Cut	Speculative Buy	$6→$5

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Benchmark Maintains Speculative Buy on Harvard Bioscience, Raises Price Target to $7.5

Benchmark analyst Bruce D. Jackson maintains Harvard Bioscience (NASDAQ:HBIO) with a Speculative Buy and raises the price target from $6 to $7.5.

Benzinga Newsdesk

PRO
Benchmark Maintains Speculative Buy on Harvard Bioscience, Raises Price Target to $6

Benchmark analyst Bruce D. Jackson maintains Harvard Bioscience (NASDAQ:HBIO) with a Speculative Buy and raises the price target from $0.6 to $6.

Benzinga Newsdesk

PRO
Benchmark Maintains Speculative Buy on Harvard Bioscience, Lowers Price Target to $0.6

Benchmark analyst Bruce D. Jackson maintains Harvard Bioscience (NASDAQ:HBIO) with a Speculative Buy and lowers the price target from $2 to $0.6.

Benzinga Newsdesk

PRO
Benchmark Maintains Speculative Buy on Harvard Bioscience, Lowers Price Target to $2

Benchmark analyst Bruce D. Jackson maintains Harvard Bioscience (NASDAQ:HBIO) with a Speculative Buy and lowers the price target from $3 to $2.

Benzinga Newsdesk

PRO
Benchmark Maintains Speculative Buy on Harvard Bioscience, Lowers Price Target to $3

Benchmark analyst Bruce Jackson maintains Harvard Bioscience (NASDAQ:HBIO) with a Speculative Buy and lowers the price target from $4.5 to $3.

Benzinga Newsdesk

PRO
Keybanc Downgrades Harvard Bioscience to Sector Weight

Keybanc analyst Paul Knight downgrades Harvard Bioscience (NASDAQ:HBIO) from Overweight to Sector Weight.

Benzinga Newsdesk

Harvard Bioscience Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Harvard Bioscience Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Benchmark Maintains Speculative Buy on Harvard Bioscience, Raises Price Target to $7.5

PRO
Benchmark Maintains Speculative Buy on Harvard Bioscience, Raises Price Target to $6

PRO
Benchmark Maintains Speculative Buy on Harvard Bioscience, Lowers Price Target to $0.6

PRO
Benchmark Maintains Speculative Buy on Harvard Bioscience, Lowers Price Target to $2

PRO
Benchmark Maintains Speculative Buy on Harvard Bioscience, Lowers Price Target to $3

PRO
Keybanc Downgrades Harvard Bioscience to Sector Weight

People Also Watch

People Also Watch

Harvard Bioscience Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Harvard Bioscience Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROBenchmark Maintains Speculative Buy on Harvard Bioscience, Raises Price Target to $7.5

PROBenchmark Maintains Speculative Buy on Harvard Bioscience, Raises Price Target to $6

PROBenchmark Maintains Speculative Buy on Harvard Bioscience, Lowers Price Target to $0.6

PROBenchmark Maintains Speculative Buy on Harvard Bioscience, Lowers Price Target to $2

PROBenchmark Maintains Speculative Buy on Harvard Bioscience, Lowers Price Target to $3

PROKeybanc Downgrades Harvard Bioscience to Sector Weight

People Also Watch

People Also Watch

PRO
Benchmark Maintains Speculative Buy on Harvard Bioscience, Raises Price Target to $7.5

PRO
Benchmark Maintains Speculative Buy on Harvard Bioscience, Raises Price Target to $6

PRO
Benchmark Maintains Speculative Buy on Harvard Bioscience, Lowers Price Target to $0.6

PRO
Benchmark Maintains Speculative Buy on Harvard Bioscience, Lowers Price Target to $2

PRO
Benchmark Maintains Speculative Buy on Harvard Bioscience, Lowers Price Target to $3

PRO
Keybanc Downgrades Harvard Bioscience to Sector Weight